For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for 3M Company (MMM) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Low · Gem Score -47 (−100…+100 Quality+Value blend) · Quality -24 · Value -65 · Sentiment -17 (timing only, not weighted) · Composite fair value $8.16 vs $182.90 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
3M Company
MMM NYSE3M Company is a diversified industrial conglomerate that develops and sells a broad portfolio of science-based products used in manufacturing, safety, transportation, electronics, healthcare, and consumer markets. The company serves customers through business segments that include Safety and Industrial, Transportation and Electronics, and Consumer, offering solutions such as abrasives, adhesives, tapes, personal protective equipment, films, filtration products, and household goods. 3M Company supports a wide range of industries with materials and technologies designed for production efficiency, worker protection, product assembly, and everyday use. Its products are distributed to businesses, institutions, and consumers across global markets, making it a significant supplier in industrial materials and applied technology.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 6.00
Total Equity: $4.75B
Shares: 541,300,000
Total Debt: $12.60B
Cash: $5.24B
EBITDA: $5.94B
Total Debt: $12.60B
Cash: $5.24B
Revenue: $24.95B
Revenue: $24.95B
Revenue: $24.95B
Total Equity: $4.75B
Tax Rate: 23.8%
Equity: $4.75B
Total Debt: $12.60B
Cash: $5.24B
Current Liabilities: $9.60B
Long-Term Debt: $10.93B
Total Debt: $12.60B
Total Equity: $4.75B
Shares: 541,300,000
Shares: 541,300,000
CapEx: -$910.00M
Shares: 541,300,000
Stock Price: $182.90
Net Income: $3.25B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 6, 2026 8:07am (17d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $35.4B | $34.2B | $32.7B | $24.6B | $24.9B |
| Cost of Revenue | $18.8B | $19.2B | $18.5B | $14.4B | $15.0B |
| Gross Profit | $16.6B | $15.0B | $14.2B | $10.1B | $10.0B |
| Operating Expenses | $9.2B | $8.5B | $23.3B | $5.3B | $5.3B |
| Operating Income | $7.4B | $6.5B | -$9.1B | $4.8B | $4.6B |
| Net Income | $5.9B | $5.8B | -$7.0B | $4.2B | $3.3B |
| EBITDA | $9.3B | $8.4B | -$7.1B | $6.2B | $5.9B |
| EPS | $10.23 | $10.21 | $-12.63 | $7.58 | $6.05 |
| EPS (Diluted) | $10.12 | $10.18 | $-12.63 | $7.55 | $6.00 |
Balance Sheet (Annual)
Last updated: Aug 6, 2026 8:07am (17d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $4.6B | $3.7B | $5.9B | $5.6B | $5.2B |
| Total Current Assets | $15.4B | $14.7B | $16.4B | $15.9B | $16.4B |
| Total Assets | $47.1B | $46.5B | $50.6B | $39.9B | $37.7B |
| Current Liabilities | $9.0B | $9.5B | $15.3B | $11.3B | $9.6B |
| Long-Term Debt | $16.1B | $14.0B | $13.1B | $11.1B | $10.9B |
| Total Liabilities | $32.0B | $31.7B | $45.7B | $36.0B | $33.0B |
| Total Equity | $15.1B | $14.8B | $4.9B | $3.9B | $4.7B |
| Retained Earnings | $45.8B | $48.0B | $37.5B | $36.8B | $38.3B |
Cash Flow (Annual)
Last updated: Aug 6, 2026 8:07am (17d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $7.5B | $5.6B | $6.7B | $1.8B | $2.3B |
| Capital Expenditure | -$1.6B | -$1.7B | -$1.6B | -$1.2B | -$910.0M |
| Free Cash Flow | $5.9B | $3.8B | $5.1B | $638.0M | $1.4B |
| Acquisitions (net) | $0 | $0 | — | — | — |
| Net Debt Issued / (Repaid) | $1.1B | $1.5B | $6.1B | $11.9B | $2.9B |
| Dividends Paid | -$3.4B | -$3.4B | -$3.3B | -$2.0B | -$1.6B |
| Stock Buybacks | -$2.2B | -$1.5B | -$33.0M | -$1.8B | -$3.3B |
| Net Change in Cash | -$70.0M | -$909.0M | $2.3B | -$333.0M | -$365.0M |
Growth Trends (YoY %)
Last updated: Aug 6, 2026 8:07am (17d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -3.2% | -4.5% | -24.8% | +1.5% |
| Gross Profit Growth | -9.4% | -5.3% | -28.7% | -1.7% |
| Operating Income Growth | -11.3% | -239.6% | +152.8% | -4.0% |
| Net Income Growth | -2.4% | -221.1% | +159.7% | -22.1% |
| EBITDA Growth | -9.8% | -185.3% | +186.6% | -4.0% |
Dividend History (Last 20)
Last updated: Aug 6, 2026 7:38am (17d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-05-22 | $0.78 | — | — | — |
| 2026-02-13 | $0.78 | — | — | — |
| 2025-11-14 | $0.73 | — | — | — |
| 2025-08-25 | $0.73 | — | — | — |
| 2025-05-23 | $0.73 | — | — | — |
| 2025-02-14 | $0.73 | — | — | — |
| 2024-11-15 | $0.70 | — | — | — |
| 2024-08-26 | $0.70 | — | — | — |
| 2024-05-23 | $0.70 | — | — | — |
| 2024-02-15 | $1.26 | — | — | — |
| 2023-11-16 | $1.25 | — | — | — |
| 2023-08-18 | $1.05 | — | — | — |
| 2023-05-18 | $1.25 | — | — | — |
| 2023-02-16 | $1.25 | — | — | — |
| 2022-11-17 | $1.25 | — | — | — |
| 2022-08-19 | $1.25 | — | — | — |
| 2022-05-19 | $1.25 | — | — | — |
| 2022-02-17 | $1.25 | — | — | — |
| 2021-11-18 | $1.24 | — | — | — |
| 2021-08-20 | $1.24 | — | — | — |
Deep Analysis
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-19 09:08Even the bull case prices 69% below today — the ratio here measures the model-vs-market gap, not payoff odds. Another quarter like the worst recent one costs 79%.
| Case | Growth | Margin | Fair value | vs price ($182.90) |
|---|---|---|---|---|
| Bull — recovery | -2% | 15.9% | $56.08 | -69% |
| Base — stabilizes | -4% | 13.8% | $46.43 | -75% |
| Bear — keeps slipping | -6% | 11.7% | $37.81 | -79% |
| Stress — last quarter repeats | +2% | 8.6% | $37.58 | -79% |
Narrative Economics
market-narrative step).
Claude Reading
The raw quarterly tape actually looks better than the models' gloom suggests. Q2 2026 revenue of $6.50B is up 2.5% YoY from $6.34B, with net income of $933M (14.4% margin) versus $723M (11.4%) — that's ~29% earnings growth on the most recent print. Trailing four quarters give ~$25.2B revenue and ~$3.0B net income, roughly in line with the 2025 annual base. The 2021→2025 revenue "collapse" from $35.4B to $25B is almost entirely the Solventum healthcare spin (completed April 2024) plus divestitures, not organic decay — the pre-flight model treating this as distress is a category error. Stripping the spin, the underlying industrial franchise is flat-to-slightly-growing with margins recovering toward mid-teens net. The -12.6% revenue CAGR and -47.5% FCF CAGR are spin-contaminated artifacts.
That said, the valuation is genuinely stretched on any honest read. At $182.90, MMM trades at ~31x trailing earnings, 4.1x EV/sales, 17x EV/EBITDA, and 20.9x book (the book multiple is distorted by $7B of accumulated litigation charges compressing equity to $4.75B; ROE of 68% is a denominator artifact, not a quality signal). FCF of $1.40B against a $94B market cap is a ~1.5% FCF yield — for a mid-single-digit organic grower with $12.6B gross debt, ongoing PFAS/earplug cash outflows (the $6B and $10B settlements are multi-year cash drags not fully reflected in headline earnings), and a 1.65% dividend yield that was cut post-spin. Peers like ETN and HON trade at 25-30x but with genuine growth; ITW at 24x with better margins. Fair multiple here is 18-22x on ~$5.75 normalized EPS run-rate, i.e., $115-130.
The synthesis verdict of $7.87 fair value is absurd and should be discarded — it's a DCF blown up by terminal-value assumptions the narrative layer itself flagged as fragile (2224% gap). The market narrative read (fallen-angel, anchored, moderate durability) is more useful and roughly correct: price is being held up by activist optionality, litigation-clearance hope, and dividend defenders. The thesis-eval framing — "priced for litigation to vanish AND 43% FCF growth" — captures the real problem: you need both to justify $183. Insider activity is genuinely negative signal quality — seven sales, zero open-market buys, all option-exercise-and-dump patterns. Not a smoking gun for a large-cap, but no insider is stepping up here either.
The contrarian bull case worth taking seriously: if Roman-era restructuring delivers 200-300bps of margin expansion on a stabilized $25-26B revenue base, and PFAS cash outflows peak in 2026-2027 rather than extending indefinitely, normalized FCF could reach $3.5-4B by 2028, making current price ~24x that number — expensive but not insane for a de-risked industrial. But this requires the market to be right about litigation finality, which the PFAS scientific/regulatory tail (drinking water standards still being litigated, medical monitoring class actions still forming) makes improbable on any near-term horizon. The bear cases in the thesis eval are weighted correctly. I dissent from the synthesis's specific fair value ($7.87 is model garbage) but agree with its directional call (overvalued). My fair value anchor is $115-135 based on 20-23x normalized $5.75-6.00 EPS, discounted modestly for litigation tail risk and offset by activist optionality. At $183, you're paying ~40% premium to that range for hope. I'd want $140 or lower to get interested, and would happily short into any $200+ print driven by activist headlines rather than earnings.
GPT Reading
At $182.9, 3M is being valued like a cleaned-up high-quality industrial compounder, but the raw numbers still look like a shrinking franchise with weakened cash conversion and a balance sheet/book value profile distorted enough to make traditional quality signals dangerous. Revenue has fallen from $35.4B in 2021 to $25.0B in 2025, a roughly 29% drop in four years, and even if 2023 included major dislocations, the post-reset base is not showing meaningful growth: 2025 revenue was just $24.95B versus $24.58B in 2024, up only 1.5%. Quarterly sales are similarly stagnant, from $5.95B in 1Q25 to $6.03B in 1Q26 and $6.34B in 2Q25 to $6.50B in 2Q26. That is stabilization, not revival. Yet the stock trades at 30.5x earnings, 4.0x sales, and 17.3x EV/EBITDA—multiples I would expect on a cleaner grower, not a conglomerate with low top-line momentum and unresolved questions around normalized cash generation.
The biggest issue for me is that earnings quality is not earning the valuation. In 2025, net income was $3.25B, but operating cash flow was only $2.31B and free cash flow only $1.40B after $910M of capex. On a $94.3B market cap, that is an FCF yield of about 1.5%. Even using net debt-adjusted enterprise value, the cash yield is still meager. If this were a temporary trough before a sharp recovery, I could excuse it, but the recent quarter pattern does not show that kind of inflection. Net income margins moved from 18.7% in 1Q25 down to 11.4% in 2Q25, 12.8% in 3Q25, 9.4% in 4Q25, 10.8% in 1Q26, then back up to 14.4% in 2Q26. That is decent profitability, but not the kind of consistent high-teens earnings power that would justify paying over 20x normalized FCF. The market seems to be capitalizing accounting recovery faster than cash recovery.
The balance sheet also argues against complacency. Debt of $12.6B against cash of $5.24B gives roughly $7.4B of net debt, manageable on the surface, but total equity is only $4.75B, which is why price-to-book blows out to 20.9x and debt-to-equity sits at 2.65x. I do not think price-to-book itself is the right metric for 3M, because legal charges and asset adjustments can make book value nearly meaningless; but when equity has been compressed this far, it is a reminder that there is less buffer for surprises than the “blue-chip industrial” label implies. The annual operating margin of 18.6% and ROIC of 29.1% look excellent, but they sit awkwardly beside the weak free cash flow and four-year revenue collapse. That contradiction makes me distrust the superficially attractive profitability metrics more than I trust them.
The strongest argument against my bearish read is that the business may already have crossed the valley. The last four quarters of revenue sum to about $25.2B, slightly ahead of 2025’s $24.95B run rate, and the latest quarter’s $933M of net income on $6.50B of sales is one of the better recent prints. If 3M can hold a 14%-15% net margin on a stable $25B-$26B revenue base, annual earnings power could move toward $3.6B-$3.9B without needing much growth, which would bring the P/E down from 30x into the mid-20s. Bulls would also say that 2023 was an exceptional legal-reset year, so using the 2021-2025 revenue decline overstates underlying deterioration. That is fair, and it is why I do not think this is a broken company. I just think the stock price already discounts most of that rehabilitation while ignoring how anemic the cash generation remains relative to equity value.
What would change my mind is evidence that the company can translate stabilization into real owner earnings. Specifically, I would want to see annual free cash flow recover from $1.40B to at least $3B, with operating cash flow above net income rather than below it, while revenue grows beyond the current $25B plateau and holds there for several quarters. If the next 12 months show something like $6.4B-$6.7B quarterly revenue with net margins consistently above 13% and FCF conversion normalizing, then $183 would look much less demanding. Absent that, I think the market is paying a premium multiple for a repair story that is only half repaired.
Grok Reading
The numbers describe a post-spin industrial that has stopped shrinking but has not restarted compounding. After the healthcare separation and the 2023 litigation wipeout (–$7.0B net income on $32.7B revenue), 3M has settled into a roughly $25B revenue run-rate: $24.58B in 2024, $24.95B in 2025, and recent quarters printing $6.0–6.5B with only +1.5% year-over-year growth. Net income recovered to $4.17B then slipped to $3.25B; the latest quarter’s $933M on $6.50B (14.4% margin) looks cleaner than the 9–11% prints that preceded it, yet free cash flow for 2025 was just $1.40B against $2.31B of operating cash flow and $910M of capex. At a $94.3B enterprise that produces a 1.5% FCF yield and trades at 30.5× trailing earnings and 17.3× EV/EBITDA, the market is already capitalizing a full legal clean-up plus material margin recovery that the cash-flow statement has not yet delivered. Book equity of only $4.75B against $12.6B of debt produces the optically absurd 20.9× P/B and 68% ROE; those ratios are artifacts of reserve charges, not evidence of a fortress franchise.
What stands out is the divergence between reported profitability and cash conversion. Operating margin sits at a respectable 18.6% and ROIC at 29%, yet FCF has compounded at –47.5% and quality is flagged as poor. Revenue confidence is low and the quarterly trend is decelerating. Insider activity is uniformly option exercise followed by immediate sale—neutral at best, zero accumulation. The 1.65% dividend, covered at a 48% payout, is affordable but no longer the 3%-plus yield that once anchored the stock; the payout is now a modest return of capital on an expensive multiple rather than a margin of safety.
The strongest contrary case rests on three data points a bull would correctly emphasize. First, the core returns remain high: 29% ROIC and 40% gross margins indicate the adhesives, safety, and industrial franchises still earn economic rents even after the spin. Second, sequential margin improvement into mid-2026 ($933M net, 14.4%) and activist presence (Elliott, Soroban) raise the probability of further cost-out or portfolio actions that could lift FCF toward the $3B zone. Third, if PFAS and residual earplug liabilities prove fully reserved and non-recurring, the current 30× multiple on trough-ish earnings could compress into a mid-teens forward multiple on normalized $4B-plus net income, making today’s price merely early rather than wrong. Those arguments have force; I simply weigh the $1.4B FCF reality and flat top line more heavily than the optionality of litigation finality and activist catalysis that are already partially in the price.
I would reverse to neutral or better only on sustained free-cash-flow above $3.0B for two consecutive years, organic revenue growth reliably above 3%, or a definitive, capped global PFAS resolution that removes the residual tail. Until then the stock screens as a mature earner priced for a pristine second act it has not yet earned.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Revenue collapsed from $35.36B in 2021 to $24.95B in 2025 — a roughly 29% decline, largely reflecting the Solventum health-care spin plus litigation-driven restructuring. Gross margin has slid every year from 46.8% to 39.9%, and operating margin from 20.8% to 18.6%, with a -27.9% operating margin hit in 2023 from litigation charges (Combat Arms/PFAS). Net income in 2025 of $3.25B against FCF of just $1.40B (OCF/NI 0.48x) signals materially weaker cash conversion than headline earnings imply — FCF fell from $5.85B in 2021 to $638M in 2024 before a modest bounce. Poor FCF quality flag is warranted. Balance sheet carries roughly $12.6B net debt against $5.24B cash; Altman Z of 4.42 says solvency is fine, but there is no cushion. Dilution discipline is a genuine strength: diluted shares fell from 585M to 541M (-1.9% CAGR), SBC only 0.9% of revenue, buyback/SBC ratio 660% — per-share value is being concentrated. Accruals -4.3% and Beneish -2.27 suggest no earnings manipulation. Insider tape is routine option-exercise-and-sell; no open-market buys but not a red flag either.
Verify before trusting this (5)
- Remaining PFAS and Combat Arms settlement cash outflows scheduled through 2030+ and their impact on future FCF
- Post-Solventum organic revenue growth rate excluding divestiture effects
- Segment margin trajectory (Safety and Industrial vs Transportation and Electronics vs Consumer)
- Terms and maturity ladder of the $12B+ gross debt stack
- Whether the SBC/buyback pace is sustainable alongside settlement funding and the dividend
The e2e composite fair value of $8.16 (and signal-adjusted $7.87) is a runaway output — almost certainly an EPV floor distorted by the 2023 -$7B litigation loss flowing through trailing earnings. I discard it as unusable rather than take it literally. That leaves me to triangulate manually: MMM does roughly $6-7 of normalized EPS on a de-Solventum'd base, carries meaningful net debt, and owes $9B+ in staged litigation payments (PFAS, Combat Arms) that are real cash, not accounting noise. A generous 17-19x on ~$7.50 normalized EPS gets to a deserved value in the $130-145 zone before litigation NPV; net that liability against equity and fair value likely sits closer to $150-165.
Verify before trusting this (5)
- Normalized post-Solventum EPS run-rate in next 2-3 quarters
- Updated PFAS/Combat Arms cash payment schedule and any settlement true-ups
- Free cash flow conversion ex-litigation — is the 60-70% of net income gap closing?
- Organic revenue growth turning positive vs continued shrinkage
- Management capital allocation: buybacks vs debt paydown priority
MMM sits in a Risk-On tape (VIX 14.9, indices at highs) with a beta of 1.08, so it should catch a mild market bid - but this is a defensive-industrial conglomerate, not a high-beta story stock, so the tape's lift lands softly. The active narrative is fallen-angel with only moderate intensity and low cult coefficient: the market is neither loving nor hating this name, it is largely ignoring it while it grinds through litigation and restructuring. That absence of a narrative bid is itself a passive headwind in an environment where capital is chasing stories. Recent price action (+1.5% short-term vs -12.6% longer CAGR, +34pp over 3y) hints at basing behavior consistent with a slow rehabilitation trade rather than a fresh momentum push. News flow this week centers on industrial peers (ITT, GFF) beating and raising - a mildly positive read-through for the group tone, but not a MMM-specific catalyst. Macro is a modest drag: 10y at 4.69% and market PE 26 make rate-sensitive, low-growth industrials less attractive vs shinier cohorts, and the $9B+ asbestos/talc liability tail keeps a persistent risk discount embedded in sentiment. Net: a low-drama name in a calm tape, with narrative apathy and legal overhang offsetting the risk-on backdrop and peer read-through.
Verify before trusting this (4)
- Any headline on asbestos/talc settlement progress or reserve adjustments - would flip the narrative fast either way
- Analyst target revisions post next print; a cluster of upgrades would validate the fallen-angel rehab thesis
- Sector rotation into defensive industrials if the risk-on tape wobbles
- Activist or spin-off chatter that could reintroduce a catalyst-driven bid
This lens hasn't been run for this ticker yet.
When we made this prediction on Aug 10, 2026, MMM was $182.90. We expect it to be $160.00 by Feb 2027, and we consider it great value under $155.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 10, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.